Author + information
- Yuichi J. Shimada,
- Laurie Farrell,
- Robert Gerszten and
- Michael Fifer
Background: It is sometimes challenging to distinguish hypertrophic cardiomyopathy (HCM) from other cardiac conditions such as hypertensive heart disease. The present study utilized metabolite profiling, a novel technology that measures serum concentrations of biochemical substances, to distinguish patients with HCM from others. We hypothesized that at least 1 metabolite has different concentration between HCM and control subjects.
Methods: We performed metabolite profiling in 3 different sets of cohorts. Cohort 1 consisted of patients with HCM who underwent alcohol septal ablation (case) and patients without HCM who underwent catheter-based closure of patent foramen ovale (control). Cohort 2 consisted of patients with HCM (case) who underwent exercise testing (ET) and patients with hypertensive heart disease who had ET (control). Cohort 3 consisted of patients with HCM who underwent ET (case) and normal volunteers who had ET (control). Case and control were matched for age, sex, and body mass index. Metabolite profiling was performed on 210 metabolites using targeted liquid chromatography-mass spectrometry methodology. The median coefficient of variation was < 15%. Student's t-test or the Mann-Whitney-Wilcoxon test was performed to determine the association between the variable and disease status.
Results: For Cohort 1 (42 cases/ 24 controls), 6 metabolites had significantly different concentrations between the 2 groups at an α level of 0.05, including 1 metabolite at an α level of 0.005. Metabolites that differentiated between the 2 groups included cysteamine, niacinamide, and threonine. For Cohort 2 (15 cases/ 15 controls), after adjusting for age, sex, and creatinine, there were 8 metabolites that had significant differences at an α level of 0.05, including 3 metabolites with an α level of 0.01. For Cohort 3 (15 cases/ 15 controls), there were 3 metabolites that had significant differences at an α level of 0.05, including 1 metabolite at an α level of 0.01. α-glycerophosphocholine and histamine had significant differences in both Cohort 2 and Cohort 3.
Conclusions: Metabolite profiling may be useful in distinguishing between HCM and other cardiac conditions.
Poster Hall, Hall C
Saturday, March 18, 2017, 9:45 a.m.-10:30 a.m.
Session Title: Advances in HCM, PPCM and Other Cardiomyopathies
Abstract Category: 13. Heart Failure and Cardiomyopathies: Clinical
Presentation Number: 1201-277
- 2017 American College of Cardiology Foundation